INTERVENTION 1:	Intervention	0
Sulforaphane Supplement	Intervention	1
sulforaphane	CHEBI:47807	0-12
Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.	Intervention	2
extract	BAO:0003070	38-45
broccoli sprout extract: Given orally	Intervention	3
extract	BAO:0003070	16-23
INTERVENTION 2:	Intervention	4
Placebo	Intervention	5
Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.	Intervention	6
placebo: Given orally	Intervention	7
INCLUSION CRITERIA:	Eligibility	0
Diagnostic mammogram	Eligibility	1
English speaking	Eligibility	2
EXCLUSION CRITERIA:	Eligibility	3
Pregnancy (as determined by urine human chorionic gonadotropin (hCG) test)	Eligibility	4
urine	UBERON:0001088	28-33
chorionic gonadotropin	CHEBI:81570	40-62
No biopsy referral after diagnostic mammogram	Eligibility	5
Patient reported breast feeding	Eligibility	6
patient	HADO:0000008,OAE:0001817	0-7
breast	UBERON:0000310	17-23
Significant active medical illness which in the opinion of the investigator would preclude protocol treatment	Eligibility	7
active	PATO:0002354	12-18
History of or active liver disease or baseline total bilirubin greater than institutional upper limit of normal	Eligibility	8
history	BFO:0000182	0-7
active	PATO:0002354	14-20
liver disease	DOID:409	21-34
Patient reported allergy or sensitivity to cruciferous vegetables	Eligibility	9
patient	HADO:0000008,OAE:0001817	0-7
allergy	HP:0012393	17-24
Use of oral antibiotics within three months prior to randomization	Eligibility	10
Oral steroid therapy at enrollment	Eligibility	11
steroid	CHEBI:35341	5-12
Current therapy with valproate acid or SAHA	Eligibility	12
valproate	CHEBI:60654	21-30
acid	CHEBI:37527	31-35
Current use of nutrient supplements or herbal remedies containing sulforaphane and unwillingness or inability to quit 72 hours prior to randomization and for the duration of the trial	Eligibility	13
nutrient	CHEBI:33284	15-23
sulforaphane	CHEBI:47807	66-78
duration	PATO:0001309	162-170
Radiation for currently-diagnosed disease prior to or during study supplementation	Eligibility	14
disease	DOID:4,OGMS:0000031	34-41
Chemotherapy for currently-diagnosed disease prior to or during study supplementation	Eligibility	15
disease	DOID:4,OGMS:0000031	37-44
Outcome Measurement:	Results	0
Change in Isothiocyanate in Urine Samples as Assessed at Baseline and After Completion of Study Therapy	Results	1
isothiocyanate	CHEBI:52221	10-24
urine	UBERON:0001088	28-33
Isothiocyante including sulforaphane in micromolar (ÂµM) concentration was measured following standard chemical measurement procedures and divided by the creatinine values in millimolar (mM) concentration.	Results	2
sulforaphane	CHEBI:47807	24-36
micromolar	UO:0000064	40-50
creatinine	CHEBI:16737	153-163
millimolar	UO:0000063	174-184
Time frame: Baseline and end of study (up to 8 weeks)	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Sulforaphane Supplement	Results	5
sulforaphane	CHEBI:47807	17-29
Arm/Group Description: Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.	Results	6
extract	BAO:0003070	61-68
broccoli sprout extract: Given orally	Results	7
extract	BAO:0003070	16-23
Overall Number of Participants Analyzed: 27	Results	8
Mean (Standard Error)	Results	9
mean	BAO:0002173	0-4
Unit of Measure:  M/mM creatinine  1.00         (0.334)	Results	10
creatinine	CHEBI:16737	23-33
Results 2:	Results	11
Arm/Group Title: Placebo	Results	12
Arm/Group Description: Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.	Results	13
placebo: Given orally	Results	14
Overall Number of Participants Analyzed: 27	Results	15
Mean (Standard Error)	Results	16
mean	BAO:0002173	0-4
Unit of Measure:  M/mM creatinine  -0.05         (0.02)	Results	17
creatinine	CHEBI:16737	23-33
Adverse Events 1:	Adverse Events	0
Total: 0/27 (0.00%)	Adverse Events	1
Adverse Events 2:	Adverse Events	2
Total: 0/27 (0.00%)	Adverse Events	3
